Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Tours | OTHER |
| University Hospital, Grenoble | OTHER |
| Central Hospital, Nancy, France | OTHER |
| University Hospital, Limoges |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main hypothesis is that NSAIDs exposure is associated with a specific severity of community-acquired bacterial infection, marked by dissemination, suppurative complications or even invasive procedures requirement.
Our objectives are also to:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patient | Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery. | ||
| control | Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| exposure to NSAIDs | The risk studied is the exposure to NSAIDs, the overall medication history will be collected for cases and controls. The standard questionnaire to document medications history, including self-medication, was previously published (Asseray et al., 2013) The window of exposure to drugs is defined as 14 days before hospital admission. Drug exposure will be assessed at the time of inclusion. | From the inclusion (J0) to the the end of hospital stay, up to three months |
| Measure | Description | Time Frame |
|---|---|---|
| Name of NSAIDS | Describe what NSAIDs terms of use contribute to the risk of serious bacterial infections | 36 months |
| type of bacterial infection at risk of worsening when exposed to NSAIDs | Describe what type of bacterial infection is at risk of worsening when exposed to NSAIDs. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Arm type: patient Arm description: adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
Arm type: control Arm description: Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site Pairing criteria (case/control analysis): age/Charlson score/type of infection/centre
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Olivier Epaulard, PU-PH | University Hospital, Grenoble | Principal Investigator |
| Eric DENES, PH | University Hospital, Limoges | Principal Investigator |
| Thomas Guimard, PH | LA ROCHE SUR YON HOSPITAL | Principal Investigator |
| Louis BENARD, PU-PH | Tours University Hospital | Principal Investigator |
| Thierry MAY, PU-PH | Central Hospital, Nancy, France | Principal Investigator |
| Annie-Pierre JONVILLE-BERA, PH | Tours University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nantes | Nantes | 44093 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001424 | Bacterial Infections |
| ID | Term |
|---|---|
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| OTHER |
| LA ROCHE SUR YON HOSPITAL | UNKNOWN |
| Agence Nationale de sécurité du Médicament | OTHER |
Not provided
Not provided
Not provided
| 36 months |
| other drugs exposure assessed by questionnaire | 36 months |
| Duration of NSAID exposure | 36 months |
| self-medication assessment | 36 months |